ライフサイエンスコーパス: calcinosis

1 zation (hyperphosphataemic familial tumoural calcinosis).

2 e of nephrocalcinosis and dystrophic cardiac calcinosis.

3 elop nephrocalcinosis and dystrophic cardiac calcinosis.

4 s performed to assess for acroosteolysis and calcinosis.

5 ating as well as decreasing the incidence of calcinosis.

6 lantation has also led to improvement of the calcinosis.

7 erosis and systemic lupus erythematosus with calcinosis.

8 nd 2 additional patients (4%) had persistent calcinosis.

9 s spectrum that includes an association with calcinosis.

10 leles was protective, for the development of calcinosis.

11 e MRI changes can precede the development of calcinosis.

12 frequently complicated by the development of calcinosis.

13 rs (15 [55.6%] vs 173 [36.1%]; P = .04), and calcinosis (15 [55.6%] vs 115 [24.0%]; P < .01).

14 of SSc, including synovitis, tenosynovitis, calcinosis, acroosteolysis, and distal vascularization a

15 Dystrophic cardiac calcinosis, an age-related cardiomyopathy that occurs am

16 distal vascularization and is sensitive for calcinosis and acroosteolysis detection.

17 quency of US features, sensitivity of US for calcinosis and acroosteolysis, and respective confidence

18 An association between calcinosis and both interstitial lung disease and anti-M

19 ad to severe hyperphosphatemia as in tumoral calcinosis and chronic kidney disease (CKD).

20 chanism may underlie the development of both calcinosis and fingertip ulcers in patients with DM.

21 ndicitis was missed at US, whereas medullary calcinosis and myelolipoma were missed at CT.

22 0, which appears to have an association with calcinosis and p155 with lipodystrophy), cytokine polymo

23 es such as arthroplasty, excision of painful calcinosis, and digital sympathectomy have been employed

24 of vasculopathy, including acro-osteolysis, calcinosis, and digital ulcers.

25 capsular hematoma, cholelithiasis, medullary calcinosis, and myelolipoma.

26 JDM or for developing complications such as calcinosis, and the clinical findings of persistent nail

27 Other extramuscular manifestations, such as calcinosis, are particularly difficult to treat, and stu

28 utaneous edema developed clinically apparent calcinosis at the same location within 9 months.

29 Many agents have been used for treatment of calcinosis but none has been accepted as a standard ther

30 Calcinosis cutis affects 20-40% of patients with systemi

31 a 12-year history of SLE who presented with calcinosis cutis at the time of SLE diagnosis developed

32 Recent data on therapy for calcinosis cutis highlights that more prospective studie

33 Calcinosis cutis is common in several connective tissue

34 It is characterized by calcinosis cutis, Raynaud's phenomenon, esophageal invol

35 Clinical features of the CREST (calcinosis cutis, Raynaud's syndrome, esophageal dysmoti

36 s well as the proposed medical therapies for calcinosis cutis.

37 cularly CA, as potential therapies to target calcinosis cutis: these should now be investigated in hu

38 Dystrophic cardiac calcinosis (DCC) occurs in certain inbred strains of mic

39 Calcinosis, defined as the presence of calcium depositio

40 ulting in hyperphosphatemic familial tumoral calcinosis due to impaired glycosylation of the phosphat

41 Additional outcome measures were onset of calcinosis, effect of treatment on height, and complicat

42 Patients with vs those without calcinosis had a longer disease duration (median, 6.9 ye

43 using a pharmaceutical dissolution model of calcinosis (hydroxyapatite (HAp) tablet), prior to evalu

44 mperfecta), mineralization (familial tumoral calcinosis/hyperostosis hyperphosphatemia syndrome, hypo

45 Risk factors for calcinosis in adults with DM have not been extensively s

46 sease duration were strongly associated with calcinosis in all multivariate models, independent of th

47 genetic loci determining dystrophic cardiac calcinosis in an F2 intercross of resistant C57BL/6J and

48 scuss the most recently published data about calcinosis in connective-tissue diseases with emphasis o

49 An exception is identifying calcinosis in patients with myositis; there is some evid

50 and is associated with an increased risk of calcinosis in young patients.

51 PURPOSE OF REVIEW: Calcinosis is a recognized manifestation of many connect

52 Familial tumoral calcinosis is characterized by ectopic calcifications an

53 RECENT FINDINGS: Calcinosis is more common in patients with sustained dis

54 Our data suggest that calcinosis is positively associated with longer disease

55 Normophosphatemic familial tumoral calcinosis (NFTC) is caused by mutations in the SAMD9 ge

56 Autoantibodies to NXP-2 were associated with calcinosis (odds ratio, 15.52; 95% CI, 2.01-119.90), whe

57 esponse to treatment, comorbidities (such as calcinosis) or outcome.

58 tissues, as exemplified by familial tumoral calcinosis, pseudoxanthoma elasticum, generalized arteri

59 iffer by altering collagen or through medial calcinosis, raise the blood pressure, increase shearing

60 th diffuse and limited scleroderma or CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility,

61 CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction

62 Sera from patients with diffuse SSc, calcinosis, Raynaud's, esophageal dysmotility, sclerodac

63 ars, digital-tip ulcers, telangiectasia, and calcinosis than those with ssSSc, in part related to inc

64 Calcinosis was a relatively uncommon clinical feature in

65 Calcinosis was found in 17 patients (39%) with US, with

66 h anti-p140 antibodies, the association with calcinosis was significant compared with the rest of the

67 persistent weakness, muscle dysfunction, and calcinosis were most frequent (23-30%) at the last evalu

68 20% of adults with dermatomyositis (DM) have calcinosis, which can lead to significant morbidity.

69 r-old girl who presented with severe tumoral calcinosis with dural and carotid artery calcifications.

70 e primarily aimed at treating the process of calcinosis with varying success.

71 Fourteen patients (11.1%) had calcinosis, with the extremities most commonly involved.